Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | THRB | P10828 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | ACR | P10323 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034151 | 0.99 | MAPT (0.38) | KMT2AMAPTTHRBPTGS2TP53 | |
| SCHEMBL14507240 | 0.90 | KMT2A (0.47) | KMT2AMAPTTHRBTP53CCNC | |
| SCHEMBL12731097 | 0.88 | MAPT (0.45) | KMT2AMAPTTHRBTP53CCNC | |
| SCHEMBL5961774 | 0.88 | THRB (0.43) | KMT2AMAPTTHRBTP53PRSS1 | |
| SCHEMBL5961761 | 0.86 | TP53 (0.43) | KMT2AMAPTTHRBTP53 | |
| SCHEMBL10120919 | 0.80 | KMT2A (0.56) | KMT2AMAPTTHRBPTGS2TP53 | |
| SCHEMBL10071027 | 0.78 | HIF1A (0.34) | KMT2AMAPTPRSS1ACRHIF1A | |
| SCHEMBL10074564 | 0.76 | KMT2A (0.59) | KMT2AMAPTTHRBCCNCCDK8 | |
| SCHEMBL12962521 | 0.76 | KMT2A (0.59) | KMT2AMAPTTHRBCCNCCDK8 | |
| SCHEMBL13206937 | 0.76 | ALDH1A1 (0.41) | KMT2AMAPTTP53CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168734-B2 | Lateral alpha-substituted acrylate compound and polymer thereof | JNC CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | CHISSO CORPORATION (JP) | 2011-06-16 | — | — | US | disclosed |
| US-7919648-B2 | Lateral α-substituted acrylate compound and polymer thereof | CHISSO CORPORATION (JP) | 2011-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144293-A1 | LATERAL ALPHA-SUBSTITUTED ACRYLATE COMPOUND AND POLYMER THEREOF | LEF1, AFF1, CNKSR1 | KMT2A 1856/4885MAPT 3921/4885THRB 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.